K Triantafyllias1, R Leiß2, M Dreher2, A Schwarting3,4. 1. ACURA Rheumazentrum Rheinland-Pfalz, Kaiser-Wilhelm-Straße 9-11, 55543, Bad Kreuznach, Deutschland. 2. Schwerpunkt Rheumatologie und klinische Immunologie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland. 3. ACURA Rheumazentrum Rheinland-Pfalz, Kaiser-Wilhelm-Straße 9-11, 55543, Bad Kreuznach, Deutschland. schwarting@uni-mainz.de. 4. Schwerpunkt Rheumatologie und klinische Immunologie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland. schwarting@uni-mainz.de.
Abstract
BACKGROUND AND OBJECTIVE: For patients with established rheumatoid arthritis and also early arthritis an increased prevalence of depression has been described. For a better understanding of depression in early arthritis patients, depression prevalences of a German early arthritis cohort were examined, with a focus on disease activity, anti-CCP status, disease duration and functional capacity over a period of 2 years. MATERIAL AND METHODS: The evaluation was based on the early arthritis cohort ADAPTHERA from Rhineland-Palatinate. The inclusion criterion was a symptom duration before diagnosis of a maximum of 1 year. Data from the disease activity score 28 (DAS28), the Health Assessment Questionnaire (HAQ, functional status), the WHO-5 Well-Being Index (WHO-5, well-being and depressive symptoms) and the Patient Health Questionnaire-9 (PHQ-9, depressive symptoms) were collected. RESULTS: At the beginning, 43.5% of patients had depressive symptoms (WHO-5 > 28). After the 2 year follow-up the percentage of patients with depressive symptoms had reduced to 20.8%. Correlations with disease activity according to DAS28 and the function of HAQ could be confirmed. There was no correlation between depressive symptoms and anti-CCP status (p = 0.431) or duration from symptom onset to diagnosis (p = 0.671). CONCLUSION: Screening of early arthritis patients for the presence of depressive symptoms is of essential importance. Patients seem to be at high risk of developing depressive symptoms especially at the beginning of the disease and when showing high disability and poor results on disease activity score (DAS28 and visual analog scale).
BACKGROUND AND OBJECTIVE: For patients with established rheumatoid arthritis and also early arthritis an increased prevalence of depression has been described. For a better understanding of depression in early arthritispatients, depression prevalences of a German early arthritis cohort were examined, with a focus on disease activity, anti-CCP status, disease duration and functional capacity over a period of 2 years. MATERIAL AND METHODS: The evaluation was based on the early arthritis cohort ADAPTHERA from Rhineland-Palatinate. The inclusion criterion was a symptom duration before diagnosis of a maximum of 1 year. Data from the disease activity score 28 (DAS28), the Health Assessment Questionnaire (HAQ, functional status), the WHO-5 Well-Being Index (WHO-5, well-being and depressive symptoms) and the Patient Health Questionnaire-9 (PHQ-9, depressive symptoms) were collected. RESULTS: At the beginning, 43.5% of patients had depressive symptoms (WHO-5 > 28). After the 2 year follow-up the percentage of patients with depressive symptoms had reduced to 20.8%. Correlations with disease activity according to DAS28 and the function of HAQ could be confirmed. There was no correlation between depressive symptoms and anti-CCP status (p = 0.431) or duration from symptom onset to diagnosis (p = 0.671). CONCLUSION: Screening of early arthritispatients for the presence of depressive symptoms is of essential importance. Patients seem to be at high risk of developing depressive symptoms especially at the beginning of the disease and when showing high disability and poor results on disease activity score (DAS28 and visual analog scale).
Authors: Matthias Englbrecht; Rieke Alten; Martin Aringer; Christoph G Baerwald; Harald Burkhardt; Nancy Eby; Gerhard Fliedner; Bettina Gauger; Ulf Henkemeier; Michael W Hofmann; Stefan Kleinert; Christian Kneitz; Klaus Krueger; Christoph Pohl; Anne-Eve Roske; Georg Schett; Marc Schmalzing; Anne-Kathrin Tausche; Hans Peter Tony; Joerg Wendler Journal: Arthritis Care Res (Hoboken) Date: 2017-01 Impact factor: 4.794
Authors: K Benesova; H-M Lorenz; V Lion; A Voigt; A Krause; O Sander; M Schneider; M Feuchtenberger; A Nigg; J Leipe; S Briem; E Tiessen; F Haas; M Rihl; D Meyer-Olson; X Baraliakos; J Braun; A Schwarting; M Dreher; T Witte; G Assmann; K Hoeper; R E Schmidt; P Bartz-Bazzanella; M Gaubitz; C Specker Journal: Z Rheumatol Date: 2019-10 Impact factor: 1.372